TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Diagnosis of type 2 diabetes mellitus~Exclusion Criteria~* History of type 1 diabetes mellitus~* Has undergone a surgical procedure within the prior 4 weeks.~* Current participation in, or has participated, in another study with an investigational device or compound, with the prior 12 weeks, and/or is not willing to refrain from participating in any other study while participating in this study~* Hypersensitivity or contraindication to any sulfonylurea (e.g., glimepiride) medication~* Has been on an investigational or approved dipeptidyl peptidase-4 (DPP-4) inhibitor agent (e.g., sitagliptin, saxagliptin)~* Presence of human immunodeficiency virus (HIV)~* Current participation in a weight loss program or is receiving weight loss medication~* History of blood disorder, certain cancers, heart, liver or kidney disease~* Current or past use of recreational or illicit drugs, or a history of drug abuse or dependence, or increased alcohol consumption

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin phosphate 100 mg or 50 mg once daily (QD)
- Glimepiride (Type: ACTIVE_COMPARATOR): Glimepiride 1-6 mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Proportion Tested: Age 3 or older~* Proportion Tested: Received testing at study testing site~* Individual Survey: 15 or older~Exclusion Criteria:~• Individual Survey: Unable to understand Spanish or English or another language translated by a qualified translator at a 5th grade level

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Promotores (Type: EXPERIMENTAL): The Promotores de Salud intervention involves specified outreach and psychoeducation on SARS-CoV-2 health related behaviors.
- Control (Type: ACTIVE_COMPARATOR): Services as usual includes outreach as usual strategies and pamphlets on site at events.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a male or female subject 40 years of age or older~* Subject must have a negative pregnancy test, and must be prepared to use effective contraception if of child-bearing potential~* Subject is capable of performing reproducible spirometry maneuvers~* Subject has post-bronchodilator FEV1/FVC ratio \<0.7~* Subject has moderate-to-severe stable COPD (Stage 2 or 3 according to the GOLD Guidelines)~* Subject has a post-bronchodilator FEV1 greater than or equal to 30% and less than 80% of predicted normal~* Subject has a current or past smoking history of at least 10 pack-years.~Exclusion Criteria:~* Subject has a significant respiratory disease or disorder other than COPD that would affect the interpretation of data from this study~* Subject has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergic or beta-agonist agents~* Subject suffers from any medical condition that would preclude the use of inhaled anticholinergic agents~* Subject has been hospitalized for COPD or pneumonia within 12 weeks~* Subject requires long-term oxygen therapy (\>15 hours a day)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- 44 mcg (Type: EXPERIMENTAL): TD-4208
- 88 mcg (Type: EXPERIMENTAL): TD-4208
- 175 mcg (Type: EXPERIMENTAL): TD-4208
- 350 mcg (Type: EXPERIMENTAL): TD-4208

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has a previous diagnosis of multiple myeloma.~2. Patient requires retreatment for multiple myeloma~3. Patient has measurable M component in serum or urine at study screening~Exclusion Criteria:~1. Patient who has progressed under all prior lines of anti MM therapy~2. Patient who has been treated by bortezomib before, and did not reach at least a minor response under this therapy, or progressed under it or within 60 days of last dose~3. Patient has shown intolerance to bortezomib or to dexamethasone or components of these drugs or has any contraindication to one or the other drug , following locally applicable prescribing information~4. Patient received prior treatment with DAC inhibitors including panobinostat~5. Patient has impaired cardiac function, or a prolonged QTc interval at screening ECG~6. Patient taking medications with relative risk of prolonging the QT interval or inducing Torsade de pointes~7. Female patient who is pregnant or breast feeding or with childbearing potential and not willing to use a double method of contraception up to 3 months after the end of study treatment. Male patient who is not willing to use a barrier method of contraception up to 3 months after the end of study treatment.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panobinostat + Bortezomib + Dexamethasone (Type: EXPERIMENTAL): None
- Placebo + Bortezomib + Dexamethasone (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Shoulder Corticosteroid Injection in Diabetic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Consent to participate in the study.~* Severe overall pain and night pain: Numerical Rating Scale (NRS) for pain\[8\] above or equal to 60/100; the scale was modified from 0-10 to 0-100 (0 = no pain 100 = unbearable pain).~* No significant improvement after at least 2 courses of physiotherapy (including direct assistance from a physical therapist with specific exercises, manual therapy, and physical agents in order to reduce inflammation and pain).~* Clinical signs of subacromial tendinobursitis, with or without signs of rotator cuff tear, defined as positive Neer, Yocum and Hawkins tests\[9-15\]. Pain experienced during the execution of these tests needed to reproduce the type of pain that patients complained the most.~* No indication for surgery due to the age, concomitant comorbidities or patient's refusal to undergo surgery.~* Well-controlled type-2 diabetes, defined as:~  * Fasting and pre-prandial blood glucose levels in the range of 90- 150mg/dL.~ * Hb1Ac \<64mmol/mol (corresponding to 8%) measured within 6 months.~* A device for self-measurement of blood sugar levels at home~* Patients need to have a recent (within 6 months) x-ray and an MRI or ultrasound of the affected shoulder~Exclusion Criteria:~* Corticosteroid treatment in the past 3 months.~* Complaints of shoulder stiffness more than shoulder pain.~* Symptomatic glenohumeral arthritis defined as shoulder stiffness plus moderate radiographic signs of arthritis (grade \>2 according to Hamada classification and grade \>1 according to Samilson-Prieto classification for eccentric and concentric arthritis respectively).~* Shoulder trauma within 3 months of inclusion evaluation for in this study.~* High blood pressure values (systolic blood pressure \>140mmHg, diastolic blood pressure \>80mmHg).~* Glaucoma.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects who have completed previous rFVIIIFc studies (NCT01181128, NCT02083965, NCT01458106 and NCT02502149)~* Ability to understand purposes and risks of the study and to provide signed and dated informed consent (or assent, as applicable).~Key Exclusion Criteria:~* Confirmed positive high-titer inhibitor (≥5.00 BU/mL).~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On-Demand (Type: EXPERIMENTAL): The individual dose of rFVIIIFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor VIII (FVIII) levels.
- Prophylaxis (Type: EXPERIMENTAL): Tailored prophylaxis, Weekly prophylaxis or Personalized prophylaxis available.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ages 18 - 80~* Chronic kidney disease (CKD) - eGFR 15 to \< 60 mL/min/1.73m2 at screening~* Hyperkalemia, defined as a serum potassium value of 5.1 to \< 6.5 mEq/L at screening~* Taking either an Angiotensin-Converting Enzyme (ACE) Inhibitor, an Angiotensin II receptor blocker (ARB), or an aldosterone antagonist (AA) medication~* Informed consent given~Exclusion Criteria:~* Participants with auto-immune related chronic kidney disease such as lupus nephritis or renal scleroderma/scleroderma renal crisis, or mixed connective tissue disease with renal involvement~* Participants with uncontrolled Type 1 diabetes, defined as or a HbA1c \> 10.0 %, or hospitalization to treat hyper- or hypo-glycemia in the past 3 months within the previous 6 months in participants with Type 2 diabetes~* Participants with severe heart failure, defined as NYHA (New York Heart Association) class IV~* Participants with major surgery including thoracic and cardiac, in the past 3 months, or participants with heart or kidney transplant~* Participants with significant cardiovascular or cerebrovascular events in the past 2 months, such as cardiac arrest, myocardial infarction, or stroke~* Participants with BMI ≥ 40 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patiromer (Type: ACTIVE_COMPARATOR): Patiromer was administered twice a day as a powder mixed with water.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was administered twice a day as a powder mixed with water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nonresponders to full dose PEG-IFN/RBV therapy~* Liver biopsy within the last 2 year~Exclusion Criteria:~* Intolerance to one of the study drugs~* Coinfection with HIV/HBV

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- on treatment nonresponders (Type: EXPERIMENTAL): naive patients with null response to peginterferon/ribavirin at week 12 or partial response at week 24
- Nonresponders to previous antiviral combination therapy (Type: EXPERIMENTAL): Nonresponders defined by viral status at weeks 4,12, and 24 of previous peginterferon/ribavirin combination therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transplantation of Autologous Oral Mucosal Epithelial Sheets for Limbal Stem-cell Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Among patients with bilateral limbal stem-cell deficiency, those who meet all the criteria listed below when they give their informed consent to participate in this research will be included.~  1. Patients in whom the eye(s) (subject to the interventional therapy) show(s) loss or dysfunction of corneal epithelial stem cells throughout the total\* circumference of the cornea~ 2. Patients in whom the corneal surface of the eye(s) (subject to the investigational therapy) is(are) entirely enveloped by conjunctival tissue~ 3. Patients of both genders aged ≥20 years when they give their informed consent~ 4. Patients who have given their own written consent to participate in this clinical research (The target disease is bilateral limbal stem-cell deficiency, although it is not always necessary that the both eyes of the patient meet the inclusion criteria.)~Exclusion Criteria:~1. Patients who are or may be pregnant, and patients who are breast feeding~2. Patients with infections (HBV, HCV, HIV, HTLV-1)~3. Patients with extreme hypolacrimation resistant to therapy~4. Patients from whom oral mucosal specimens cannot be collected because clear scar formation or inflammatory findings are noted in a cell-collection site of the mucosal membrane~5. Patients whose score of Performance Status (PS\*) is 3 or more~6. Any others who are judged by the chief subinvestigator to be ineligible for this clinical research, due to the presence of complications, etc.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mucosal cell sheet transplantation (Type: EXPERIMENTAL): The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* A clinical diagnosis of HAE type I or II~* Documented HAE attacks within a defined calendar period~* Access to acute attack medications~* Sexually active women of child-bearing potential and sexually active men must utilize effective contraception~Key Exclusion Criteria:~* Women who are pregnant or breast-feeding~* Any clinical condition or medical history that would interfere with the subject's safety or ability to participate in the study~* Use of C1INH, androgens or tranexamic acid for prophylaxis of HAE attacks~* History of or current alcohol or drug abuse~* Infection with hepatitis B, hepatitis C or HIV~* Participation in any other investigational drug study currently or within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: BCX7353 350 mg once daily (Type: EXPERIMENTAL): BCX7353 capsules, 350 mg dose administered once per day for 28 days
- Parts 2 and 3: BCX7353 250 mg once daily (Type: EXPERIMENTAL): BCX7353 capsules, 250 mg dose administered once per day for 28 days
- Parts 2 and 3: BCX7353 125 mg once daily (Type: EXPERIMENTAL): BCX7353 capsules, 125 mg dose administered once per day for 28 days
- Parts 1, 2 and 3: Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules, administered once per day for 28 days
- Part 3: BCX7353 62.5 mg once daily (Type: EXPERIMENTAL): BCX7353 capsules, 62.5 mg dose administered once per day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Criteria for inclusion were positivity for T cruzi as confirmed by 2 or more serological tests (indirect immunofluorescence, ELISA, and/or indirect hemagglutination) and having cardiomyopathy.~* Cardiomyopathy was present when at least 3 of the following criteria were fulfilled:~  * LV enddiastolic diameter (LVDD) N55 mm~ * LVDD/body surface area \> 2.7cm/m2~ * LV ejection fraction (LVEF) \< 55%~ * QRS interval \> 120 ms~ * echocardiographic evidence of diffuse or segmental systolic wall motion abnormalities.~Exclusion Criteria:~* Exclusion criteria were being pregnant~* Using any h-blocker~* Having additional comorbidities (eg, hypertension, diabetes mellitus, thyroid dysfunction, chronic obstructive pulmonary disease, asthma, and renal or hepatic failure).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RASi plus placebo (Type: PLACEBO_COMPARATOR): RAS inhibition was optimized and after patients were randomly assigned to receive placebo
- RASi plus carvedilol (Type: EXPERIMENTAL): RAS inhibition was optimized and after patients were randomly assigned to receive carvedilol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Active AS patients (as judged by the treating MD) who are currently employed.~* Patients who are scheduled by their rheumatologist to initiate treatment with Etanercept.~Exclusion Criteria:~* Patients who initiated a procedure for eligibility of work disability/pension.~* Patients with previous use of TNF-alpha inhibitors either in commercial use, or in a study for the treatment of AS or a related spondylarthropathy condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AS patients who are working and treated with Enbrel (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: FAMILY_BASED
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Individuals thought to have schizophrenia or schizoaffective disorder, be the parent of such an individual, or be in the matched control group of unrelated individuals not thought to have schizophrenia or schizoaffective disorder~Exclusion Criteria:~* Unable to give informed consent;~* Psychotic disorder judged to be secondary to substance abuse, psychotic disorder that appears to be secondary to a known medical or neurological disorder, or severe mental retardation

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- Diagnostic (Type: None): A diagnostic was performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete